Nat Med:CXCR4拮抗剂+PD-1抑制剂+化疗三联疗法治疗胰腺癌获突破

2020-05-27 奇点 奇点

近期公布的临床试验COMBAT(KEYNOTE-202)的数据显示,新型CXCR4抑制剂BL-8040(Motixafortide),配合PD-1抑制剂和化疗联合使用,在胰腺癌的二线/三线治疗中初步效

近期公布的临床试验COMBAT(KEYNOTE-202)的数据显示,新型CXCR4抑制剂BL-8040(Motixafortide),配合PD-1抑制剂和化疗联合使用,在胰腺癌的二线/三线治疗中初步效果良好。此前报道:BioLineRx宣布其CXCL4拮抗剂BL-8040与Keytruda联合治疗转移性胰腺癌的2b临床活性 这种三联疗法,在试验中作为二线治疗使用,疾病控制率达到77%,其中35%的患者实现了客观缓解,缓解持续时间达到7.8个月,这些数据都是胰腺癌治疗多年来难得的进步[1]。相关数据发表在《自然·医学》上。   (图片来源:Nature Reviews Clinical Oncology) 对于胰腺癌为什么难治,科学家们已经总结出了不少原因,其中很重要的一条就是肿瘤微环境当中,CD8+T细胞的数量实在是太少。即使免疫检查点抑制剂能穿越重重屏障抵达肿瘤部位,也很难调动起足够强大的抗肿瘤免疫应答[2]。 所以要想让PD-1抑制剂们具备挑战胰腺癌的能力,就得给它配上可靠的队友。本次试验中使用的CXCR4抑制剂,就是近年来颇受关注的新星,因为很多癌细胞都存在CXCR4的

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1852386, encodeId=61031852386d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 30 12:38:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884348, encodeId=5d37188434840, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 20 09:38:47 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805128, encodeId=fdef8051280b, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>免疫治疗获益仍然十分有限, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:15:55 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601603, encodeId=9e81601603bf, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>多联治疗,暂时效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 11:47:20 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278944, encodeId=c25d12e894418, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412459, encodeId=622f1412459ad, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511761, encodeId=384e1511e6100, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610504, encodeId=80f3161050423, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613728, encodeId=bd2c1613e2817, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600673, encodeId=61056006e3b9, content=不小的突破!ORR如此之高!未来还要看PFS,OS👍👍🍋🍋🍅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 27 23:52:13 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
    2020-07-30 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=1852386, encodeId=61031852386d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 30 12:38:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884348, encodeId=5d37188434840, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 20 09:38:47 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805128, encodeId=fdef8051280b, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>免疫治疗获益仍然十分有限, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:15:55 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601603, encodeId=9e81601603bf, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>多联治疗,暂时效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 11:47:20 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278944, encodeId=c25d12e894418, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412459, encodeId=622f1412459ad, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511761, encodeId=384e1511e6100, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610504, encodeId=80f3161050423, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613728, encodeId=bd2c1613e2817, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600673, encodeId=61056006e3b9, content=不小的突破!ORR如此之高!未来还要看PFS,OS👍👍🍋🍋🍅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 27 23:52:13 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
    2021-02-20 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1852386, encodeId=61031852386d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 30 12:38:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884348, encodeId=5d37188434840, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 20 09:38:47 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805128, encodeId=fdef8051280b, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>免疫治疗获益仍然十分有限, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:15:55 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601603, encodeId=9e81601603bf, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>多联治疗,暂时效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 11:47:20 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278944, encodeId=c25d12e894418, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412459, encodeId=622f1412459ad, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511761, encodeId=384e1511e6100, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610504, encodeId=80f3161050423, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613728, encodeId=bd2c1613e2817, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600673, encodeId=61056006e3b9, content=不小的突破!ORR如此之高!未来还要看PFS,OS👍👍🍋🍋🍅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 27 23:52:13 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
    2020-07-30 lovetcm

    #胰腺癌#免疫治疗获益仍然十分有限

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1852386, encodeId=61031852386d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 30 12:38:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884348, encodeId=5d37188434840, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 20 09:38:47 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805128, encodeId=fdef8051280b, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>免疫治疗获益仍然十分有限, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:15:55 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601603, encodeId=9e81601603bf, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>多联治疗,暂时效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 11:47:20 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278944, encodeId=c25d12e894418, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412459, encodeId=622f1412459ad, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511761, encodeId=384e1511e6100, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610504, encodeId=80f3161050423, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613728, encodeId=bd2c1613e2817, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600673, encodeId=61056006e3b9, content=不小的突破!ORR如此之高!未来还要看PFS,OS👍👍🍋🍋🍅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 27 23:52:13 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
    2020-06-06 lovetcm

    #胰腺癌#多联治疗,暂时效果不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1852386, encodeId=61031852386d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 30 12:38:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884348, encodeId=5d37188434840, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 20 09:38:47 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805128, encodeId=fdef8051280b, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>免疫治疗获益仍然十分有限, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:15:55 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601603, encodeId=9e81601603bf, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>多联治疗,暂时效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 11:47:20 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278944, encodeId=c25d12e894418, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412459, encodeId=622f1412459ad, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511761, encodeId=384e1511e6100, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610504, encodeId=80f3161050423, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613728, encodeId=bd2c1613e2817, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600673, encodeId=61056006e3b9, content=不小的突破!ORR如此之高!未来还要看PFS,OS👍👍🍋🍋🍅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 27 23:52:13 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1852386, encodeId=61031852386d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 30 12:38:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884348, encodeId=5d37188434840, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 20 09:38:47 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805128, encodeId=fdef8051280b, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>免疫治疗获益仍然十分有限, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:15:55 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601603, encodeId=9e81601603bf, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>多联治疗,暂时效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 11:47:20 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278944, encodeId=c25d12e894418, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412459, encodeId=622f1412459ad, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511761, encodeId=384e1511e6100, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610504, encodeId=80f3161050423, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613728, encodeId=bd2c1613e2817, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600673, encodeId=61056006e3b9, content=不小的突破!ORR如此之高!未来还要看PFS,OS👍👍🍋🍋🍅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 27 23:52:13 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
    2020-05-29 chenwq09
  7. [GetPortalCommentsPageByObjectIdResponse(id=1852386, encodeId=61031852386d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 30 12:38:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884348, encodeId=5d37188434840, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 20 09:38:47 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805128, encodeId=fdef8051280b, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>免疫治疗获益仍然十分有限, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:15:55 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601603, encodeId=9e81601603bf, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>多联治疗,暂时效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 11:47:20 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278944, encodeId=c25d12e894418, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412459, encodeId=622f1412459ad, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511761, encodeId=384e1511e6100, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610504, encodeId=80f3161050423, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613728, encodeId=bd2c1613e2817, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600673, encodeId=61056006e3b9, content=不小的突破!ORR如此之高!未来还要看PFS,OS👍👍🍋🍋🍅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 27 23:52:13 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1852386, encodeId=61031852386d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 30 12:38:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884348, encodeId=5d37188434840, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 20 09:38:47 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805128, encodeId=fdef8051280b, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>免疫治疗获益仍然十分有限, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:15:55 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601603, encodeId=9e81601603bf, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>多联治疗,暂时效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 11:47:20 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278944, encodeId=c25d12e894418, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412459, encodeId=622f1412459ad, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511761, encodeId=384e1511e6100, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610504, encodeId=80f3161050423, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613728, encodeId=bd2c1613e2817, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600673, encodeId=61056006e3b9, content=不小的突破!ORR如此之高!未来还要看PFS,OS👍👍🍋🍋🍅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 27 23:52:13 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1852386, encodeId=61031852386d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 30 12:38:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884348, encodeId=5d37188434840, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 20 09:38:47 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805128, encodeId=fdef8051280b, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>免疫治疗获益仍然十分有限, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:15:55 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601603, encodeId=9e81601603bf, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>多联治疗,暂时效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 11:47:20 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278944, encodeId=c25d12e894418, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412459, encodeId=622f1412459ad, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511761, encodeId=384e1511e6100, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610504, encodeId=80f3161050423, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613728, encodeId=bd2c1613e2817, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600673, encodeId=61056006e3b9, content=不小的突破!ORR如此之高!未来还要看PFS,OS👍👍🍋🍋🍅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 27 23:52:13 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1852386, encodeId=61031852386d7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 30 12:38:47 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884348, encodeId=5d37188434840, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Feb 20 09:38:47 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805128, encodeId=fdef8051280b, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>免疫治疗获益仍然十分有限, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jul 30 00:15:55 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601603, encodeId=9e81601603bf, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>多联治疗,暂时效果不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Jun 06 11:47:20 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278944, encodeId=c25d12e894418, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13913, encryptionId=70e6139138a, topicName=PD-1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412459, encodeId=622f1412459ad, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511761, encodeId=384e1511e6100, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610504, encodeId=80f3161050423, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613728, encodeId=bd2c1613e2817, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Fri May 29 14:38:47 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600673, encodeId=61056006e3b9, content=不小的突破!ORR如此之高!未来还要看PFS,OS👍👍🍋🍋🍅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed May 27 23:52:13 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
    2020-05-27 lovetcm

    不小的突破!ORR如此之高!未来还要看PFS,OS👍👍🍋🍋🍅

    0

相关资讯

J Control Release:研究发现治疗胰腺癌的新疗法

免疫疗法在癌症治疗中显示出巨大的潜力。然而,对于诸如胰腺癌之类的免疫抑制肿瘤,免疫疗法远不能令人满意。PI3K-γ和集落刺激因子-1/集落刺激因子-1受体(CSF-1/CSF-1R)途径参

Cancer Cell:癌王又一秘笈被破解!研究发现,肿瘤新抗原反倒会促进胰腺癌进展,增强树突状细胞功能可破解

胰腺癌可以说是当之无愧的癌王,转移快,复发率高,生存期短,就连免疫治疗这个大杀器都对它无可奈何。

Cell Death Dis:YY1/miR-548t-5p/CXCL11通路调节胰腺癌细胞的增殖和转移

胰腺导管腺癌(PDAC)是美国癌症死亡的第四大主要原因,其5年生存率仅约为9%。手术是治愈胰腺癌(PC)的唯一方法,然而只有5-20%的患者有机会接受手术,即便如此,经手术治疗的患者的中位生存期不超过

NATURE:胰腺癌是怎么逃过免疫监视的?

胰腺导管腺癌(PDAC)对包括ICB在内的大多数疗法具有耐药性。在PDAC中,导致MHC-I缺损的突变很少被发现,尽管MHC-I的表达被频繁下调。

病例丨胰腺癌治疗策略分享

患者女性,63岁,2019-10-09因间断性上腹部疼痛1年,加重1周就诊。

Nature:新突破:胰腺癌治疗新方法——羟化氯喹+化疗

胰腺癌是一种恶性程度很高,诊断和治疗都很困难的消化道恶性肿瘤,约90%为起源于胰管上皮的导管腺癌。其发病率和死亡率近年来明显上升。胰腺癌有病程短、病情发展快和迅速恶化等特点,是预后最差的恶性肿瘤之一。